Thursday, November 21, 2024 11/21/2024

Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda

Award Number: R01AI150523
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Schistosoma mansoni (Sm) and hepatitis B virus (HBV) are both endemic infections in sub-Saharan Africa with substantial prevalence, morbidity and mortality. In Uganda, prevalence estimates for Sm and HBV are 25% and 10%, respectively. Sm infection biases immunological responses towards Th2 and regulatory patterns which could potentially result in significant immune interactions at various stages of HBV infection. However, limited data address the clinical or immunological impact of Sm and HBV coinfection. Proposed is a clinical and mechanistic investigation to characterize the nature and magnitude of impact from Sm infection on the course of chronic HBV. Led by Ugandan investigators proficient in leading high-level research on viral hepatitis and Schistosomiases epidemiology and immunology, this study builds on long-standing collaborative work between Ugandan, US, and UK investigators and leverages substantive in-country research infrastructure and expertise. In Aim 1, we characterize the course of Sm infection in chronic HBV patients utilizing both novel and standard assays for diagnosing Sm, while concurrently establishing a cohort of individuals for longer-term investigation. In Aim 2, we systematically evaluate HBV serology, virology and clinical measures of disease (e.g., Fibroscan, ultrasound) at study entry compared to six months post praziquantel treatment, and then over up to three years of follow-up. In Aim 3, we explore focused immunological studies comparing liver biopsy to peripheral blood samples to evaluate potential mechanisms by which Sm and HBV interaction may occur. These studies support technology transfer of a novel, highly sensitive Sm assay as well as directly support the career development of several early-stage Ugandan investigators. Findings from the proposed studies will provide novel insight for improving the clinical management and mechanistic understanding of Sm and HBV coinfection, with implications for many regions of Africa with co-occurring endemics of these two infections.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $130,925 )
2024	2024	THE INFECTIOUS DISEASES INSTITUTE LIMITED	IDI-MCKINNELL KNOWLEDGE CENTRE	KAMPALA				UGA	Allergy and Infectious Diseases Research	000	5	4/18/2024	NON-COMPETING CONTINUATION	$130,925
														Subtotal = $130,925

Issue Date FY: 2023 ( Subtotal = $131,009 )
2023	2023	INFECTIOUS DISEASES INSTITUTE LIMITED	MULAGO HOSPITAL COMPLEX	KAMPALA				UGA	Allergy and Infectious Diseases Research	003	4	4/20/2023	NON-COMPETING CONTINUATION	$131,009
2023	2022	INFECTIOUS DISEASES INSTITUTE LIMITED	MULAGO HOSPITAL COMPLEX	KAMPALA				UGA	Allergy and Infectious Diseases Research	002	3	4/20/2023	NON-COMPETING CONTINUATION	$0
2023	2021	INFECTIOUS DISEASES INSTITUTE LIMITED	MULAGO HOSPITAL COMPLEX	KAMPALA				UGA	Allergy and Infectious Diseases Research	001	2	4/20/2023	NON-COMPETING CONTINUATION	$0
2023	2020	INFECTIOUS DISEASES INSTITUTE LIMITED	MULAGO HOSPITAL COMPLEX	KAMPALA				UGA	Allergy and Infectious Diseases Research	000	1	4/20/2023	NEW	$0
														Subtotal = $131,009

Issue Date FY: 2022 ( Subtotal = $132,310 )
2022	2022	INFECTIOUS DISEASES INSTITUTE LIMITED	MULAGO HOSPITAL COMPLEX	KAMPALA				UGA	Allergy and Infectious Diseases Research	000	3	6/24/2022	NON-COMPETING CONTINUATION	$132,310
														Subtotal = $132,310

Issue Date FY: 2021 ( Subtotal = $134,913 )
2021	2021	INFECTIOUS DISEASES INSTITUTE LIMITED	MULAGO HOSPITAL COMPLEX	KAMPALA				UGA	Allergy and Infectious Diseases Research	000	2	5/1/2021	NON-COMPETING CONTINUATION	$134,913
														Subtotal = $134,913

Issue Date FY: 2020 ( Subtotal = $135,000 )
2020	2020	INFECTIOUS DISEASES INSTITUTE LIMITED	MULAGO HOSPITAL COMPLEX	KAMPALA				UGA	Allergy and Infectious Diseases Research	000	1	5/8/2020	NEW	$135,000
														Subtotal = $135,000

Grand Total All Awards = $664,157

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda

Award Number: R01AI150523

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer